| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02845778 | Pharmacokinetics of Melatonin | Drug: Melatonin | Khon Kaen University | Phase 1|Phase 2 | 2016-05-01 | 2016-07-24 |
| NCT02107079 | Pharmacokinetics of Melatonin | Drug: Melatonin | Utrecht University | | 2012-01-01 | 2014-04-03 |
| NCT00790478 | Ulcerative Colitis | Dietary Supplement: Melatonin|Other: Placebo | Emory University | Phase 2 | 2009-01-01 | 2009-12-22 |
| NCT02644590 | Diabetes Mellitus, Type 1|Hypertension | Drug: Melatonin | Sheba Medical Center | Early Phase 1 | 2016-02-01 | 2015-12-30 |
| NCT01805089 | Breast Cancer | Drug: Melatonin 3 mg | Dana-Farber Cancer Institute | Early Phase 1 | 2006-10-01 | 2015-03-03 |
| NCT01858155 | Relapsed Malignant Solid Tumor | Drug: Melatonin | C17 Council | Phase 1 | 2013-05-01 | 2017-01-30 |
| NCT01705639 | Diabetes|Glucose Tolerance | Drug: Melatonin | Helsinki University|Lund University|Folkhalsan Research Center | Phase 3 | 2012-11-01 | 2017-01-03 |
| NCT00849511 | Migraine | Drug: melatonin | Nordlandssykehuset HF|University of Tromso | Phase 2 | 2009-02-01 | 2014-09-24 |
| NCT00927030 | Autistic Disorder|Insomnia | Drug: supplemental liquid melatonin|Drug: flavored liquid or liquid supplemental melatonin | Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | 2008-01-01 | 2012-06-28 |
| NCT00686907 | Blindness | Drug: Melatonin | National Eye Institute (NEI) | | 2007-03-01 | 2012-10-23 |
| NCT01370486 | Lennox-Gastaut Syndrome | Drug: melatonin|Drug: placebo | Institution de Lavigny | Phase 4 | 2011-08-01 | 2011-06-09 |
| NCT02963181 | Hypotension, Orthostatic|Hypertension|Autonomic Nervous System Diseases | Drug: Yohimbine|Drug: Melatonin | Lawson Health Research Institute | Early Phase 1 | 2017-01-01 | 2016-11-14 |
| NCT01860716 | Evidence of Liver Transplantation | Drug: Melatonin|Drug: Placebo | Aragon Institute of Health Sciences|Fondo de Investigacion Sanitaria | Phase 3 | 2013-05-01 | 2013-05-22 |
| NCT02359448 | Parkinson's Disease|Nocturia | Drug: Melatonin | University College, London | Phase 2 | 2015-04-01 | 2015-02-04 |
| NCT02768077 | Parkinson's Disease | Drug: Melatonin(Circadin庐)|Drug: Placebo | Kuhnil Pharmaceutical Co., Ltd. | Phase 4 | 2016-01-01 | 2016-05-16 |
| NCT01695070 | Fetal Growth Retardation | Drug: Melatonin | Monash University | Phase 4 | 2012-09-01 | 2014-11-14 |
| NCT01700959 | Cancer Malignancies | Drug: melatonin|Drug: placebo | St. Jude Children's Research Hospital|National Cancer Institute (NCI) | Phase 3 | 2013-01-01 | 2016-12-20 |
| NCT03013790 | Delirium|Melatonin | Drug: Melatonin | MICE Trial Group | Phase 4 | 2016-12-01 | 2017-01-04 |
| NCT02836743 | REM Sleep Behavior Disorder | Drug: Circadin|Drug: Placebo | Seoul National University Hospital | Phase 4 | 2016-01-01 | 2016-07-18 |
| NCT02536417 | Delirium | Drug: Melatonin|Drug: Sugar pill | Fraser Health | Phase 3 | 2015-09-01 | 2015-08-27 |
| NCT02454855 | Cancer | Drug: melatonin|Drug: placebo | Centre Jean Perrin | Phase 3 | 2015-05-01 | 2016-06-10 |
